Janumet (Metformin Hydrochloride, Sitagliptin)

Metformin lowers glucose production by the liver and increases peripheral insulin sensitivity. Sitagliptin blocks the DPP‑4 enzyme, raising levels of incretin hormones that stimulate insulin release and suppress glucagon in a glucose‑dependent manner. Together they reduce fasting and post‑prandial blood sugar.

The specific dose of Janumet is determined by the prescribing healthcare professional based on individual patient factors such as renal function, glycemic targets, and concomitant medications. Patients should follow the prescriber’s instructions and not adjust the dose without medical guidance.

Safety of Janumet in pregnancy or while breastfeeding has not been fully established. Metformin may be used in certain pregnancy situations under medical supervision, but sitagliptin lacks sufficient data. Women who are pregnant, planning pregnancy, or nursing should discuss risks and alternatives with their healthcare provider.

To request Janumet, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and assistance with import documentation.

Janumet combines a biguanide (metformin) with a DPP‑4 inhibitor (sitagliptin), offering dual mechanisms in a single tablet. Compared with metformin alone, it provides greater HbA1c reduction. Compared with sulfonylureas, it has a lower risk of hypoglycemia. It is an alternative to other fixed‑dose combinations such as metformin‑linagliptin.

Janumet tablets should be stored at room temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged.

Janumet is taken orally, usually with meals to reduce gastrointestinal discomfort. The tablet should be swallowed whole with a glass of water. Patients should follow the dosing schedule prescribed by their clinician and not crush or split the tablet unless instructed.

The most serious risks include lactic acidosis, a rare but potentially fatal condition linked to metformin, and pancreatitis related to sitagliptin. Severe hypoglycemia can also occur, especially when combined with insulin or sulfonylureas. Patients should seek immediate medical attention if they experience unexplained abdominal pain, rapid breathing, or signs of an allergic reaction.

Janumet is contraindicated in patients with severe renal impairment, known hypersensitivity to metformin or sitagliptin, or a history of lactic acidosis. It should also be avoided in individuals with acute or chronic metabolic acidosis, including diabetic ketoacidosis, and in those receiving iodinated contrast agents without adequate renal function monitoring.